|
|
|
29 Jun 2008 |
Liver Phase I Results Presented at WCIO 2008 & Best of ASCO(R)
|
|
26 Jun 2008 |
Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
|
|
26 Jun 2008 |
FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
|
|
26 Jun 2008 |
Thallion Receives Health Canada Approval to Initiate Phase II Study for TLN-232 in Metastatic Melanoma Patients
|
|
25 Jun 2008 |
Promising Results for Oral CP-4126
|
|
25 Jun 2008 |
IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
|
|
25 Jun 2008 |
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
|
|
25 Jun 2008 |
Genmab Initiates Study of Zalutumumab with Radiotherapy in Head and Neck Cancer
|
|
25 Jun 2008 |
MethylGene Announces the Initiation of a Randomized, Three-Arm Phase II Trial of MGCD0103 in Combination With Vidaza® in Patients With High-Risk MDS or AML
|
|
24 Jun 2008 |
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
|
|
23 Jun 2008 |
CB1400, patented by Canopus BioPharma, enters Phase II clinical trials for the prevention of mucositis in patients with cancer of the head and neck
|
|
23 Jun 2008 |
BioGeneriX and Neose Technologies Initiate Phase 2 Trial for GlycoPEG-GCSF
|
|
23 Jun 2008 |
A.P. Pharma Completes Enrollment in Phase 3 Trial of APF530
|
|
23 Jun 2008 |
FDA approves Velcade(R) (Bortezomib) for injection for patients with previously untreated multiple myeloma
|
|
22 Jun 2008 |
Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
|
|
22 Jun 2008 |
Cytokinetics Announces Third Extension of Research Term Under Collaboration with GlaxoSmithKline
|
|
19 Jun 2008 |
Bavarian Nordic reports interim data from Phase I/II studies with breast cancer vaccine
|
|
19 Jun 2008 |
Merck Applies to Extend Use of Erbitux for First-Line Head and Neck Cancer in Europe
|
|
19 Jun 2008 |
Axelar Initiates Phase I/II Clinical Trial on Cancer Patients with the New Anti-Cancer Drug AXL1717
|
|
18 Jun 2008 |
ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
|
|
18 Jun 2008 |
Algeta Begins Phase III Clinical Study of Alpharadin in Men with Advanced Prostate Cancer
|
|
18 Jun 2008 |
Molecular Insight Pharmaceuticals, Inc. Presents Three Studies on Trofex™ Program for Prostate Cancer Diagnosis and Staging
|
|
17 Jun 2008 |
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
|
|
17 Jun 2008 |
Gloucester Pharmaceuticals Announces Podium Presentation of Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
|
17 Jun 2008 |
Hybrigenics receives authorization to accelerate inecalcitol dose escalation in Phase II trial for hormone-refractory prostate cancer
|
|
17 Jun 2008 |
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
|
|
16 Jun 2008 |
Possitive Clinical Data for PBI-1402 Presented at the Annual Congress of the European Hematology Association
|
|
16 Jun 2008 |
OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's Core Technology
|
|
16 Jun 2008 |
Molecular Insight Pharmaceuticals, Inc. Reports Preclinical Data on Solazed™ for Treatment of Metastatic Melanoma at Society of Nuclear Medicine (SNM) Meeting
|
|
16 Jun 2008 |
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
|
|
16 Jun 2008 |
SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation
|
|
15 Jun 2008 |
Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia
|
|
15 Jun 2008 |
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
|
|
15 Jun 2008 |
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
|
|
15 Jun 2008 |
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
|
|
15 Jun 2008 |
MethylGene Initiates Second Phase I Clinical Trial With MGCD265, A Multi-Targeted (c-Met) Kinase Inhibitor in Patients With Solid Tumors
|
|
12 Jun 2008 |
GlaxoSmithKline receives marketing authorisation in the EU for Tyverb(R) (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer
|
|
12 Jun 2008 |
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
|
|
12 Jun 2008 |
Calando Pharmaceuticals Collaborates with City of Hope to Initiate Investigator Sponsored Clinical Trial Using IT-101 in Lymphoma Patients
|
|
11 Jun 2008 |
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
|
|
10 Jun 2008 |
Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.
|
|
09 Jun 2008 |
Study Supports Possible Use Of Leukine(R) As A Potential Adjuvant Therapy For High-Risk Melanoma Patients
|
|
09 Jun 2008 |
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
|
|
08 Jun 2008 |
TopoTarget announces positive data from a phase II study of belinostat monotherapy in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma (PTCL and CTCL) and the granting of a Fast Track designation from FDA for belinostat in PTC
|
|
08 Jun 2008 |
WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE(R) (CA9-SCAN)
|
|
08 Jun 2008 |
Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
|
05 Jun 2008 |
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
|
|
05 Jun 2008 |
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
|
|
05 Jun 2008 |
Ipsen And Spirogen's SJG-136 Shows Encouraging Results In The Treatment Of Refractory Solid Tumours At ASCO
|
|
05 Jun 2008 |
4SC to acquire Nycomed oncology projects
|
| |
|
Results 301 - 350 of 2757 |
